Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.

A comparison has been made of [(123)I]meta-iodobenzylguanidine ([(123)I]MIBG) and [(111)In]pentetreotide scintigraphy in 54 patients with a variety of neuroendocrine tumors of whom 46 patients had metastatic disease. [(111)In]Pentetreotide scintigraphy was more sensitive in detecting metastatic lesi...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Kaltsas, G, Korbonits, M, Heintz, E, Mukherjee, J, Jenkins, P, Chew, S, Reznek, R, Monson, J, Besser, G, Foley, R, Britton, K, Grossman, AB
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2001

Míreanna comhchosúla

Treatment of metastatic pheochromocytoma and paraganglioma with I-131-meta-iodobenzylguanidine (MIBG)
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2003)

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
de réir: Mukherjee, J, et al.
Foilsithe / Cruthaithe: (2001)

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2004)

Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.
de réir: Isidori, A, et al.
Foilsithe / Cruthaithe: (2002)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
de réir: King, C, et al.
Foilsithe / Cruthaithe: (1993)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
de réir: Grozinsky-Glasberg, S, et al.
Foilsithe / Cruthaithe: (2008)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
de réir: Carroll, P, et al.
Foilsithe / Cruthaithe: (2003)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2005)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
de réir: Grozinsky-Glasberg, S, et al.
Foilsithe / Cruthaithe: (2008)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
de réir: Jenkins, P, et al.
Foilsithe / Cruthaithe: (2000)

MRI of pancreatic neuroendocrine tumours.
de réir: Owen, N, et al.
Foilsithe / Cruthaithe: (2001)

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (1998)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
de réir: Ur, E, et al.
Foilsithe / Cruthaithe: (1993)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2002)

Advances in the treatment of gastroenteropancreatic neuroendocrine neoplasms with somatostatin analogs
de réir: Ming Lu, et al.
Foilsithe / Cruthaithe: (2023-03-01)

Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors
de réir: Jae Hee Cho
Foilsithe / Cruthaithe: (2016-09-01)

The diagnosis and medical management of advanced neuroendocrine tumors.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2004)

Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors
de réir: Callisia N. Clarke, et al.
Foilsithe / Cruthaithe: (2023-12-01)

The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2001)

Comments on 'Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two-year study' by Florakis et al (2000) - Reply
de réir: Monson, J, et al.
Foilsithe / Cruthaithe: (2001)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
de réir: Korbonits, M, et al.
Foilsithe / Cruthaithe: (1998)

Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment.
de réir: Putignano, P, et al.
Foilsithe / Cruthaithe: (2000)

A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.
de réir: Bomanji, J, et al.
Foilsithe / Cruthaithe: (1992)

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.
de réir: Druce, MR, et al.
Foilsithe / Cruthaithe: (2010)

Hexarelin as a test of pituitary reserve in patients with pituitary disease.
de réir: Korbonits, M, et al.
Foilsithe / Cruthaithe: (1999)

The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2001)

The role of chemotherapy management of malignant in the nonsurgical neuroendocrine tumours
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2001)

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
de réir: Chahal, H, et al.
Foilsithe / Cruthaithe: (2012)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
de réir: Ur, E, et al.
Foilsithe / Cruthaithe: (1992)

From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms
de réir: Philipp Melhorn, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI.
de réir: Rockall, A, et al.
Foilsithe / Cruthaithe: (2009)

The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.
de réir: Isidori, A, et al.
Foilsithe / Cruthaithe: (2006)

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (1998)

Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome.
de réir: Rockall, A, et al.
Foilsithe / Cruthaithe: (2003)

Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography.
de réir: Rockall, A, et al.
Foilsithe / Cruthaithe: (2003)

The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2003)

Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study
de réir: Wei Guo, et al.
Foilsithe / Cruthaithe: (2025-02-01)

How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2000)

Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
de réir: Isidori, A, et al.
Foilsithe / Cruthaithe: (2003)

A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-γ and meta-iodobenzylguanidine
de réir: Ahnert-Hilger Gudrun, et al.
Foilsithe / Cruthaithe: (2004-05-01)